ReviewFrontiers in physiology2021
Sex Differences of the Diabetic Heart.
Review in Frontiers in physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- Impact of type 2 diabetes mellitus on in-hospital outcomes in patients with ST-elevation myocardial infarction: A nationwide study in Germany.Metabolism open · 2026Article
- Single-cell insights into maladaptive endothelial plasticity and therapeutic targets in diabetic vascular complications.Cardiovascular diabetology · 2026Review
- Review
- A Four-Phenotype Model for Risk Stratification in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: The Role of Sex and Diabetes.Biomedicines · 2026Article
- Laboratory Biomarker Profiles and Phenotypic Discrimination in Coronary Artery Disease with Metabolic and Renal Comorbidities: A Cross-Sectional Study.International journal of general medicine · 2026Article
- Metformin alleviates diastolic dysfunction in mice with experimental diabetic cardiomyopathy.Journal of molecular and cellular cardiology plus · 2025Article
- Cardiac digital twins: a tool to investigate the function and treatment of the diabetic heart.Cardiovascular diabetology · 2025Review
- Impact of sex and menopausal hormonal therapy on cardiovascular diseases in people with diabetes or prediabetes.Scientific reports · 2025Article
- Type 2 diabetes worsens the outcome of ischemia/reperfusion in female STEMI patients and female db/db mice with HFpEF cardiometabolic phenotype.Cardiovascular diabetology · 2025Article
- Article
- Sex Differences in Procedural Characteristics and Clinical Outcomes Among Patients Undergoing Bifurcation PCI.Korean circulation journal · 2025Article
- Fibroblast-specific TGF-β signaling mediates cardiac dysfunction, fibrosis, and hypertrophy in obese diabetic mice.Cardiovascular research · 2024Article
- Epicardial fat and insulin resistance in healthy older adults: a cross-sectional analysis.GeroScience · 2024Article
- Article
- Article
- Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy.Cardiovascular research · 2023Review
- SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes.Journal of personalized medicine · 2023Review
- Focus on today's evidence while keeping an eye on the future: lessons derived from hypertension in women.Journal of human hypertension · 2022Review
- Molecular signature of cardiac remodeling associated with Polymerase Gamma mutation.Life sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes is a chronic disease associated with micro- and macro-vascular complications, including myocardial ischemia, and also with a specific and intrinsic cardiac dysfunction called diabetic cardiomyopathy (DCM). Both clinical and animal studies demonstrate significant sex differences in prevalence, pathophysiology, and outcomes of cardiovascular diseases (CVDs), including those associated with diabetes. The increased risk of CVDs with diabetes is higher in women compared to men with 50% higher risk of coronary artery diseases and increased mortality when exposed to acute myocardial infarction. Clinical studies also reveal a sexual dimorphism in the incidence and outcomes of DCM. Based on these clinical findings, growing experimental research was initiated to understand the impact of sex on CVDs associated with diabetes and to identify the molecular mechanisms involved. Endothelial dysfunction, atherosclerosis, coagulation, and fibrosis are mechanisms found to be sex-differentially modulated in the diabetic cardiovascular system. Recently, impairment of energy metabolism also emerged as a determinant of multiple CVDs associated with diabetes. Therefore, future studies should thoroughly analyze the sex-specific metabolic determinants to propose new therapeutic targets. With current medicine tending toward more personalized care of patients, we finally propose to discuss the importance of sex as determinant in the treatment of diabetes-associated cardiac diseases to promote a more systemic inclusion of both males and females in clinical and preclinical studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.